To evaluate the dose-dependent efficacy and safety of upadacitinib in treating rheumatoid arthritis (RA) across different patient populations, focusing on both clinical outcomes and adverse events.
Key Findings:
Nine trials with 5,237 participants were included.
Both 15 mg and 30 mg doses of upadacitinib significantly improved ACR20 response rates compared to controls, indicating strong efficacy.
No significant efficacy difference was found between the 15 mg and 30 mg doses.
Higher doses were associated with increased risk of adverse events, including serious infections and elevated liver enzymes, highlighting safety concerns.
Interpretation:
Upadacitinib shows superior efficacy in RA treatment, with both doses providing similar clinical benefits; however, the 30 mg dose carries a higher risk of adverse events, suggesting careful consideration in clinical use.
Limitations:
Limited long-term outcome data beyond 24 weeks raises concerns about the sustainability of treatment effects.
Insufficient evidence for special populations such as the elderly or those with hepatic impairment limits generalizability of findings.
Conclusion:
While upadacitinib is effective for RA, the 15 mg dose may offer a better benefit-risk balance compared to the 30 mg dose. Further studies are needed to evaluate long-term safety and efficacy, particularly in specific patient populations.
Higher oxidative balance was associated with lower mortality, while greater systemic inflammation was linked to increased risk in a US cohort of patients with rheumatoid arthritis.
